The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

LX.a

Lung cancer

There is substantial evidence that lung cancer is one longterm complication of alkylating agents used in the treatment of lymphomas including Hodgkin's disease. Abstinence from smoking in this setting is crucially important

Publications

Sapalidis K, Laskou S, Amaniti A, Mantalovas S, Giannakidis D, Koulouris C, Karapantzos I, Karapantzou C, Mponiou K, Tsiouda T, Konstantinou F, Kougioumtzi I, Katsikogiannis N, Sardeli C, Gogakos A, Schizas N, Domeyer P, Zarogoulidis P, Kesisoglou I

Lung cancer induced from chemotherapy a 20 years old case.

Respiratory medicine case reports 2018;24;32-34 — 2018 — 32-34

Bluhm EC, Ronckers C, Hayashi RJ, Neglia JP, Mertens AC, Stovall M, Meadows AT, Mitby PA, Whitton JA, Hammond S, Barker JD, Donaldson SS, Robison LL, Inskip PD

Cause-specific mortality and second cancer incidence after non-Hodgkin lymphoma: a report from the Childhood Cancer Survivor Study.

Blood 2008 Apr 15;111;4014-21 — 2008 Apr 15 — 4014-21

Lorigan P, Radford J, Howell A, Thatcher N

Lung cancer after treatment for Hodgkin's lymphoma: a systematic review.

The Lancet. Oncology 2005 Oct;6;773-9 — 2005 Oct — 773-9

Travis LB, Gilbert E

Lung cancer after Hodgkin lymphoma: the roles of chemotherapy, radiotherapy and tobacco use.

Radiation research 2005 Jun;163;695-6 — 2005 Jun — 695-6

Travis LB, Gospodarowicz M, Curtis RE, Clarke EA, Andersson M, Glimelius B, Joensuu T, Lynch CF, van Leeuwen FE, Holowaty E, Storm H, Glimelius I, Pukkala E, Stovall M, Fraumeni JF, Boice JD, Gilbert E

Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease.

Journal of the National Cancer Institute 2002 Feb 06;94;182-92 — 2002 Feb 06 — 182-92

Hancock SL, Hoppe RT, Horning SJ, Rosenberg SA

Intercurrent death after Hodgkin disease therapy in radiotherapy and adjuvant MOPP trials.

Annals of internal medicine 1988 Aug 01;109;183-9 — 1988 Aug 01 — 183-9

Horning SJ, Ang PT, Hoppe RT, Rosenberg SA

The Stanford experience with combined procarbazine, Alkeran and vinblastine (PAVe) and radiotherapy for locally extensive and advanced stage Hodgkin's disease.

Annals of oncology : official journal of the European Society for Medical Oncology 1992 Nov;3;747-54 — 1992 Nov — 747-54